Mendelian randomization study of obesity and type 2 diabetes in hospitalized COVID-19 patients.
Body Mass Index
COVID-19
/ epidemiology
Causality
Comorbidity
Diabetes Mellitus, Type 2
/ epidemiology
Genome-Wide Association Study
Hospitalization
/ statistics & numerical data
Humans
Mendelian Randomization Analysis
Obesity
/ classification
Polymorphism, Single Nucleotide
/ genetics
Risk Factors
SARS-CoV-2
Severity of Illness Index
COVID-19
Hospitalization
Mendelian randomization
Obesity
Type 2 diabetes
Journal
Metabolism: clinical and experimental
ISSN: 1532-8600
Titre abrégé: Metabolism
Pays: United States
ID NLM: 0375267
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
05
11
2021
revised:
22
01
2022
accepted:
24
01
2022
pubmed:
2
2
2022
medline:
17
3
2022
entrez:
1
2
2022
Statut:
ppublish
Résumé
Both obesity and type 2 diabetes (T2D) are reported to be highly enriched in hospitalized COVID-19 patients. Due to the close correlation between obesity and T2D, it is important to examine whether obesity and T2D are independently related to COVID-19 hospitalization. To examine the causal effect of obesity and T2D in hospitalized COVID-19 patients using Mendelian randomization (MR). This two-sample MR analysis applied genetic markers of obesity identified in the genome wide association study (GWAS) by the GIANT Consortium as instrumental variables (IVs) of obesity; and genetic markers of T2D identified by the DIAGRAM Consortium as IVs of T2D. The MR analysis was performed in hospitalized COVID-19 patient by the COVID-19 Host Genetics Initiative using the MR-Base platform. All 3 classes of obesity (Class 1/2/3) were shown as the causal risk factors of COVID-19 hospitalization; however, T2D doesn't increase the risk of hospitalization or critically ill COVID-19 as an independent factor. Obesity, but not T2D, is a primary risk factor of COVID-19 hospitalization.
Sections du résumé
BACKGROUND
Both obesity and type 2 diabetes (T2D) are reported to be highly enriched in hospitalized COVID-19 patients. Due to the close correlation between obesity and T2D, it is important to examine whether obesity and T2D are independently related to COVID-19 hospitalization.
OBJECTIVE
To examine the causal effect of obesity and T2D in hospitalized COVID-19 patients using Mendelian randomization (MR).
RESEARCH DESIGN AND METHODS
This two-sample MR analysis applied genetic markers of obesity identified in the genome wide association study (GWAS) by the GIANT Consortium as instrumental variables (IVs) of obesity; and genetic markers of T2D identified by the DIAGRAM Consortium as IVs of T2D. The MR analysis was performed in hospitalized COVID-19 patient by the COVID-19 Host Genetics Initiative using the MR-Base platform.
RESULTS
All 3 classes of obesity (Class 1/2/3) were shown as the causal risk factors of COVID-19 hospitalization; however, T2D doesn't increase the risk of hospitalization or critically ill COVID-19 as an independent factor.
CONCLUSIONS
Obesity, but not T2D, is a primary risk factor of COVID-19 hospitalization.
Identifiants
pubmed: 35101533
pii: S0026-0495(22)00034-8
doi: 10.1016/j.metabol.2022.155156
pmc: PMC8800123
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
155156Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Références
Nat Genet. 2012 Sep;44(9):981-90
pubmed: 22885922
Clin Infect Dis. 2011 Feb 1;52(3):301-12
pubmed: 21208911
JAMA. 2020 Apr 14;323(14):1406-1407
pubmed: 32083643
Nature. 2021 Dec;600(7889):472-477
pubmed: 34237774
Eur J Hum Genet. 2020 Jun;28(6):715-718
pubmed: 32404885
Diabetes Care. 2021 Dec;44(12):2790-2811
pubmed: 34711637
Obes Rev. 2020 Nov;21(11):e13128
pubmed: 32845580
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459
Innovation (Camb). 2021 May 28;2(2):100112
pubmed: 33942034
Lancet Reg Health Eur. 2021 May;4:100105
pubmed: 33969336
Lancet Diabetes Endocrinol. 2020 Jul;8(7):616-627
pubmed: 32559477
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Diabetes. 2006 Apr;55(4):1133-40
pubmed: 16567539
Clin Infect Dis. 2021 Jun 1;72(11):e695-e703
pubmed: 32945846
Sci Rep. 2021 Aug 6;11(1):16013
pubmed: 34362956
Diabetes Care. 2020 Oct;43(10):e118-e119
pubmed: 32647055
Diabetes Care. 2020 Jul;43(7):e72-e74
pubmed: 32409499
N Engl J Med. 2020 Oct 15;383(16):1522-1534
pubmed: 32558485
Elife. 2018 May 30;7:
pubmed: 29846171
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
Int Urol Nephrol. 2020 Jun;52(6):1193-1194
pubmed: 32222883
Int J Endocrinol. 2012;2012:320482
pubmed: 22675349
PLoS Med. 2021 Mar 4;18(3):e1003553
pubmed: 33661905
J Clin Endocrinol Metab. 2004 Jun;89(6):2595-600
pubmed: 15181029
Am J Hypertens. 2020 Apr 29;33(5):373-374
pubmed: 32251498
Nature. 2021 Mar;591(7848):92-98
pubmed: 33307546
Nat Genet. 2013 May;45(5):501-12
pubmed: 23563607
Best Pract Res Clin Endocrinol Metab. 2002 Dec;16(4):595-610
pubmed: 12468409
Diabetes Care. 2020 Nov;43(11):2870-2872
pubmed: 32778554
Nat Rev Endocrinol. 2021 Mar;17(3):135-149
pubmed: 33479538
Int J Infect Dis. 2016 Aug;49:129-33
pubmed: 27352628
BMJ. 2020 Apr 2;369:m1375
pubmed: 32241884
JAMA. 2017 Nov 21;318(19):1925-1926
pubmed: 29164242
Metabolism. 2022 Mar;128:155121
pubmed: 35026232
Nat Genet. 2014 Mar;46(3):234-44
pubmed: 24509480